Reuters logo
BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations
April 21, 2017 / 4:34 PM / 8 months ago

BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

April 21 (Reuters) - Gilead Sciences Inc:

* Results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

* Studies demonstrated HCV cure rates of 99 percent in children aged 6 to 11 years, and 100 percent in adult patients co-infected with HCV and HBV

* In Karen Murray led study, 1 treatment-naïve genotype 1 patient relapsed; other patients achieved SVR12, primary efficacy endpoint

* In Chun-Jen Liu led study, 3 patients had serious adverse events that were not considered to be drug-related

* Most common adverse events reported from Chun-Jen Liu led study were headache, upper respiratory infection, fatigue Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below